Alnylam Pharmaceuticals Inc. (ALNY), reported complete 18-month data from its ongoing Phase 2 open-label extension or OLE study with patisiran, an investigational RNAi therapeutic targeting transthyretin or TTR, for the treatment of hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN), also known as familial amyloidotic polyneuropathy (FAP).
from RTT - Biotech http://ift.tt/1XItQFz
via IFTTT
No comments:
Post a Comment